

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re patent application of

**Shahram MIHAN et al.**

Serial No. **10/538,540**

Filed **June 10, 2005**

For **COPOLYMERS OF ETHYLENE WITH  
ALPHA-OLEFINS**

)  
)  
)  
)  
) **Art Unit 1796**  
)  
) **Examiner R. A. Lee**  
)  
)  
)

Mail Stop Amendment  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450  
Sir:

**TRANSMITTAL LETTER**

Submitted herewith for filing in the U.S. Patent and Trademark Office are the following:


- ☒ Postcard
- ☒ Transmittal Letter
- ☒ Response and Amendment (7 pages)
- ☒ Attachment A (Amendment to the Claims) (3 pages)

The Commissioner for Patents is hereby authorized to charge the required fees, any deficiency, or credit any overpayment, to Deposit Account Number 08-2336, in relation to the above-identified application.

Respectfully submitted,

**SHAHRAM MIHAN ET AL.**

By

  
**Jarrod N. Raphael**  
Registration No. **55,566**  
**Agent for Applicant**

Basell USA Inc.  
Delaware Corporate Center II  
2 Righter Parkway, Suite 300  
Wilmington, DE 19803  
Date: **October 23, 2008**



Docket No. LU 6084

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:  
Shahram MIHAN, et al.

Serial No.: 10/538,540

Group Art Unit: 1796

Filed: June 10, 2005

Examiner: R.A. LEE

Title: COPOLYMERS OF ETHYLENE WITH ALPHA-OLEFINS

RESPONSE AND AMENDMENT UNDER 37 C.F.R. §1.111

Commissioner of Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This is in response to the Office Action bearing a mailing date of July 23, 2008. The three-month shortened statutory period to respond is set to expire on October 23, 2008. As such, this response is timely filed.

In view of the following amendments and remarks, Applicant respectfully requests the Examiner to reconsider and withdraw the outstanding objections and rejections, and allow all claims pending in this application.

**AMENDMENT**

Please amend the above captioned application as follows:

**IN THE CLAIMS:**

Please amend claims 16, 19, 27, and 28 as shown in ATTACHMENT A without any prejudice or disclaimer to the subject matter expressed therein.